Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
Yeh T-L., Leissing TM., Abboud MI., Thinnes CC., Atasoylu O., Holt-Martyn JP., Zhang D., Tumber A., Lippl K., Lohans CT., Leung IKH., Morcrette H., Clifton IJ., Claridge TDW., Kawamura A., Flashman E., Lu X., Ratcliffe PJ., Chowdhury R., Pugh CW., Schofield CJ.
Four compounds in clinical trials for anaemia treatment are potent inhibitors of the hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs), but differ in potency and how they interact with HIF at the PHD active site.